New Resistant-HTN Therapies: Target, Evidence, Status

Clinical Mastery · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Approved indications, trial results, and monitoring requirements evolve. Date-specific evidence belongs in the treatment decision, not an undated class-wide claim.

New treatments target different pressure pathways. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

New treatments target different pressure pathways. Aldosterone pathway — Synthesis or receptor-related approaches; RAAS pathway — Upstream signaling targets; Sympathetic pathway — Neural or device-related approaches; Evidence-to-use decision — Comparator, endpoint, eligibility and current status. A BP reduction in a trial is not the same as established outcome benefit or regulatory availability. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Different hormonal targets

Endothelin antagonism and aldosterone synthase inhibition intervene at different points in blood pressure regulation. Mechanism alone does not establish clinical benefit.

Confirm true resistance

Check measurement quality, out-of-office pressure, adherence, regimen adequacy, sodium and volume, and secondary causes before escalating.

Know which agent is established

Aprocitentan is an approved endothelin-receptor antagonist for hypertension uncontrolled on other agents. Baxdrostat (BAXFENDY) received U.S. approval in 2026 as an aldosterone-synthase inhibitor for add-on BP treatment. Lorundrostat has separate trial evidence; do not infer its regulatory status from baxdrostat’s approval.

Monitor the mechanism-specific harms

Aprocitentan requires attention to fluid retention, hemoglobin, liver safety, and reproductive precautions. Baxdrostat labeling calls for potassium and sodium assessment before initiation and periodically thereafter, with additional attention to hyperkalemia-producing drugs. Review the current individual label rather than applying a generic MRA protocol.

Distinguish endpoints

A reduction in measured blood pressure does not automatically establish cardiovascular or kidney-outcome benefit. Follow-up duration matters.

Distinguish trial eligibility from the label

An eGFR or potassium cutoff used for enrollment describes the studied population; it is not automatically a prescribing contraindication or proof of benefit outside that population. State the date and separate BP reduction from direct evidence of fewer cardiovascular or kidney events.

Supporting evidence

Continue learning